Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 563

1.

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brasasard A, Burkhart C, Crowell K, Eisen D, Gottlieb A, Hamzavi I, Hazen P, Jaleel T, Kimball A, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Mar 11. pii: S0190-9622(19)30367-6. doi: 10.1016/j.jaad.2019.02.067. [Epub ahead of print]

PMID:
30872156
2.

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brasasard A, Burkhart C, Crowell K, Eisen D, Gottlieb A, Hamzavi I, Hazen P, Jaleel T, Kimball A, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Mar 11. pii: S0190-9622(19)30368-8. doi: 10.1016/j.jaad.2019.02.068. [Epub ahead of print]

PMID:
30872149
3.

Strengthening Public Health Leadership in Africa: An Innovative Fellowship Program.

Kimball AM, Harper D, Creamer K, Adeyemi A, Yates R, Lillywhite L, Told M, Heymann DL.

Acad Med. 2019 Mar 12. doi: 10.1097/ACM.0000000000002707. [Epub ahead of print]

PMID:
30870155
4.

Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320).

Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, Farooqi A, Katheria A, Sauberan J, Singh J, Nelson K, Wickremasinghe A, Dong L, Hassinger DC, Aucott SW, Hayashi M, Heuchan AM, Carey WA, Derrick M, Wolf IS, Kimball A, Sankar M, Leone T, Perez J, Serize A, Clyman RI.

J Perinatol. 2019 Mar 8. doi: 10.1038/s41372-019-0347-4. [Epub ahead of print]

PMID:
30850756
5.

Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience.

Flood KS, Porter ML, Kimball AB.

J Eur Acad Dermatol Venereol. 2019 Mar 8. doi: 10.1111/jdv.15552. [Epub ahead of print]

PMID:
30848856
6.

Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.

Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C.

J Eur Acad Dermatol Venereol. 2019 Mar 5. doi: 10.1111/jdv.15400. [Epub ahead of print]

PMID:
30838709
7.

Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.

Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D.

Sci Adv. 2019 Feb 20;5(2):eaav2437. doi: 10.1126/sciadv.aav2437. eCollection 2019 Feb.

8.

Histone Methylation Directs Myeloid TLR4 Expression and Regulates Wound Healing following Cutaneous Tissue Injury.

Davis FM, Kimball A, denDekker A, Joshi AD, Boniakowski AE, Nysz D, Allen RM, Obi A, Singer K, Henke PK, Moore BB, Kunkel SL, Gallagher KA.

J Immunol. 2019 Mar 15;202(6):1777-1785. doi: 10.4049/jimmunol.1801258. Epub 2019 Feb 1.

PMID:
30710046
9.

An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life.

Storer MA, Danesh MJ, Sandhu ME, Pascoe V, Kimball AB.

Int J Womens Dermatol. 2018 Oct 11;4(4):198-202. doi: 10.1016/j.ijwd.2018.08.009. eCollection 2018 Dec.

10.

Clinical Goals and Barriers to Effective Psoriasis Care.

Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB.

Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

11.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.

Br J Dermatol. 2018 Nov 28. doi: 10.1111/bjd.17454. [Epub ahead of print]

PMID:
30485400
12.

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.

Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z, Kimball AS, Mezzi K, Ludwig H, Niesvizky R.

Blood. 2019 Jan 10;133(2):147-155. doi: 10.1182/blood-2018-06-860015. Epub 2018 Nov 26.

13.

The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis.

Kimball AB, Sundaram M, Gauthier G, Guérin A, Pivneva I, Singh R, Ganguli A.

Dermatol Ther (Heidelb). 2018 Dec;8(4):557-569. doi: 10.1007/s13555-018-0264-z. Epub 2018 Oct 10.

14.

Whole body heat exposure modulates acute glucose metabolism.

Kimball AL, McCue PM, Petrie MA, Shields RK.

Int J Hyperthermia. 2018;35(1):644-651. doi: 10.1080/02656736.2018.1516303. Epub 2018 Oct 10.

PMID:
30303421
15.

Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.

Porter ML, Golbari NM, Lockwood SJ, Kimball AB.

Semin Cutan Med Surg. 2018 Sep;37(3):182-189. doi: 10.12788/j.sder.2018.041.

PMID:
30215636
16.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):333-339. doi: 10.1111/jdv.15242. Epub 2018 Nov 22.

PMID:
30198588
17.

Predictions, Surprises, and the Future of the Dermatology Workforce.

Porter ML, Kimball AB.

JAMA Dermatol. 2018 Nov 1;154(11):1253-1255. doi: 10.1001/jamadermatol.2018.2925. No abstract available.

PMID:
30193360
18.

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.

Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31. doi: 10.1111/jdv.15233. Epub 2018 Oct 23. Review.

PMID:
30176066
19.

Online communications among hidradenitis suppurativa patients reflect community needs.

Golbari NM, Porter ML, Kimball AB.

J Am Acad Dermatol. 2018 Aug 28. pii: S0190-9622(18)32485-X. doi: 10.1016/j.jaad.2018.08.031. [Epub ahead of print] No abstract available.

PMID:
30165167
20.

Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements.

Golbari NM, Porter ML, Kimball AB.

J Drugs Dermatol. 2018 Aug 1;17(8):886-887.

PMID:
30124728
21.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

PMID:
30124721
22.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
23.

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.

Kimball AB, Tzellos T, Calimlim BM, Teixeira HD, Geng Z, Okun MM.

Acta Derm Venereol. 2018 Nov 5;98(10):932-937. doi: 10.2340/00015555-3012.

24.

Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa.

Golbari NM, Porter ML, Kimball AB.

J Am Acad Dermatol. 2019 Jan;80(1):114-119. doi: 10.1016/j.jaad.2018.06.063. Epub 2018 Jul 10.

PMID:
30003993
25.

Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.

Kimball AB, Ganguli A, Fleischer A.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2254-2256. doi: 10.1111/jdv.15163. Epub 2018 Jul 17.

PMID:
29959796
26.

Murine macrophage chemokine receptor CCR2 plays a crucial role in macrophage recruitment and regulated inflammation in wound healing.

Boniakowski AE, Kimball AS, Joshi A, Schaller M, Davis FM, denDekker A, Obi AT, Moore BB, Kunkel SL, Gallagher KA.

Eur J Immunol. 2018 Sep;48(9):1445-1455. doi: 10.1002/eji.201747400. Epub 2018 Jun 26.

PMID:
29879295
27.

Heliox Adjunct Therapy for Neonates With Congenital Diaphragmatic Hernia.

Wise AC, Boutin MA, Knodel EM, Proudfoot JA, Lane BP, Evans ML, Suttner DM, Kimball AL.

Respir Care. 2018 Sep;63(9):1147-1153. doi: 10.4187/respcare.06079. Epub 2018 May 22.

PMID:
29789411
28.

Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials.

Kimball AB, Sundaram M, Shields AL, Hudgens S, Okun M, Foley C, Ganguli A.

J Am Acad Dermatol. 2018 Dec;79(6):1141-1143. doi: 10.1016/j.jaad.2018.05.015. Epub 2018 May 19. No abstract available.

PMID:
29787843
29.

Assessment of treatment-seeking behaviour in patients with psoriasis.

Golbari NM, Lockwood SJ, Porter ML, Kimball AB.

Br J Dermatol. 2018 Oct;179(4):989-990. doi: 10.1111/bjd.16778. Epub 2018 Aug 6. No abstract available.

PMID:
29758088
30.

Clinical outcomes after varicose vein procedures in octogenarians within the Vascular Quality Initiative Varicose Vein Registry.

Sutzko DC, Obi AT, Kimball AS, Smith ME, Wakefield TW, Osborne NH.

J Vasc Surg Venous Lymphat Disord. 2018 Jul;6(4):464-470. doi: 10.1016/j.jvsv.2018.02.008. Epub 2018 May 8.

PMID:
29752187
31.

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L.

Br J Dermatol. 2018 Oct;179(4):984-986. doi: 10.1111/bjd.16737. Epub 2018 Jul 20. No abstract available.

PMID:
29747219
32.

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.

Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C.

Br J Dermatol. 2018 Sep;179(3):615-622. doi: 10.1111/bjd.16724. Epub 2018 Jul 4.

PMID:
29742274
33.

Current guidelines for psoriasis treatment: a work in progress.

Golbari NM, Porter ML, Kimball AB.

Cutis. 2018 Mar;101(3S):10-12. Review.

PMID:
29718028
34.

Response to: Remission of hidradenitis suppurativa after bariatric surgery.

Golbari NM, Lee Porter M, Kimball AB.

JAAD Case Rep. 2018 Mar 9;4(3):278-279. doi: 10.1016/j.jdcr.2017.11.024. eCollection 2018 Apr. No abstract available.

35.

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.

Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G.

J Am Acad Dermatol. 2018 Aug;79(2):294-301.e6. doi: 10.1016/j.jaad.2018.03.047. Epub 2018 Apr 10.

PMID:
29653208
36.

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.

Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F.

Arthritis Rheumatol. 2018 Sep;70(9):1399-1407. doi: 10.1002/art.40508. Epub 2018 Jul 22.

37.

Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.

Kimball A, Patil S, Koczwara B, Raman KS, Perry R, Grover S, Selvanayagam J.

Int J Cardiol. 2018 Jun 15;261:159-161. doi: 10.1016/j.ijcard.2018.03.025. Epub 2018 Mar 8.

PMID:
29576422
38.

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522. doi: 10.1111/jdv.14910. Epub 2018 Apr 10.

39.

Ly6CHi Blood Monocyte/Macrophage Drive Chronic Inflammation and Impair Wound Healing in Diabetes Mellitus.

Kimball A, Schaller M, Joshi A, Davis FM, denDekker A, Boniakowski A, Bermick J, Obi A, Moore B, Henke PK, Kunkel SL, Gallagher KA.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1102-1114. doi: 10.1161/ATVBAHA.118.310703. Epub 2018 Mar 1.

PMID:
29496661
40.

Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.

Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A.

J Drugs Dermatol. 2018 Feb 1;17(2):180-186.

PMID:
29462226
41.

Host-associated bacterial community succession during amphibian development.

Prest TL, Kimball AK, Kueneman JG, McKenzie VJ.

Mol Ecol. 2018 Apr;27(8):1992-2006. doi: 10.1111/mec.14507. Epub 2018 Mar 23.

PMID:
29411448
42.

Dysfunctional Wound Healing in Diabetic Foot Ulcers: New Crossroads.

Davis FM, Kimball A, Boniakowski A, Gallagher K.

Curr Diab Rep. 2018 Jan 23;18(1):2. doi: 10.1007/s11892-018-0970-z. Review.

PMID:
29362914
43.

Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply.

Dimopoulos MA, Kimball AS.

Lancet Oncol. 2018 Jan;19(1):e2. doi: 10.1016/S1470-2045(17)30920-8. No abstract available.

PMID:
29304357
44.

Understanding patient engagement in psoriasis treatment.

Golbari NM, Lockwood SJ, Porter ML, Kimball AB.

Br J Dermatol. 2018 Apr;178(4):988-989. doi: 10.1111/bjd.16266. Epub 2018 Mar 6. No abstract available.

PMID:
29274082
45.

A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data.

Kimball AK, Oko LM, Bullock BL, Nemenoff RA, van Dyk LF, Clambey ET.

J Immunol. 2018 Jan 1;200(1):3-22. doi: 10.4049/jimmunol.1701494.

46.

Age-induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age.

Kimball AB, Alora-Palli MB, Tamura M, Mullins LA, Soh C, Binder RL, Houston NA, Conley ED, Tung JY, Annunziata NE, Bascom CC, Isfort RJ, Jarrold BB, Kainkaryam R, Rocchetta HL, Swift DD, Tiesman JP, Toyama K, Xu J, Yan X, Osborne R.

J Am Acad Dermatol. 2018 Jan;78(1):29-39.e7. doi: 10.1016/j.jaad.2017.09.012. Epub 2017 Nov 14.

PMID:
29146147
47.

Adverse Reactions to Biologics in Psoriasis.

Lockwood SJ, Prens LM, Kimball AB.

Curr Probl Dermatol. 2018;53:1-14. doi: 10.1159/000478072. Epub 2017 Nov 7.

PMID:
29131033
48.

Amplified hearing device use in acute care settings for patients with hearing loss: A feasibility study.

Kimball AR, Roscigno CI, Jenerette CM, Hughart KM, Jenkins WW, Hsu W.

Geriatr Nurs. 2018 May - Jun;39(3):279-284. doi: 10.1016/j.gerinurse.2017.10.009. Epub 2017 Nov 10.

PMID:
29129447
49.

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A.

J Am Acad Dermatol. 2018 Jan;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051. Epub 2017 Nov 6.

50.

Telehealth Systems.

Mechanic OJ, Kimball AB.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Jan 19.

Supplemental Content

Loading ...
Support Center